BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

CAR T liver fibrosis therapy  Memorial Sloan Kettering Cancer Center researchers have generated CAR T cells against PLAUR, which is involved in extracellular matrix remodelling, that could eliminate pathologic senescent cells . Senescent cells have been...
BioCentury | Jun 4, 2020
Product Development

WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial

In the latest hit to hydroxychloroquine, a double-blind, placebo-controlled study found that use of the malaria drug as post-exposure prophylaxis doesn’t prevent COVID-19. The report comes as the WHO resumes hydroxychloroquine testing in SOLIDARITY, and...
BioCentury | Apr 29, 2020
Product Development

Thrive AACR data highlights specificity, sensitivity trade-offs for cancer screening

Data from Thrive’s prospective, multicancer blood test study makes it clear that avoiding false positives is the top priority when screening asymptomatic individuals for rare events. While that inevitably comes at the cost of sensitivity,...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B  Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 24, 2020
Regulation

人人为我,我为人人: 协调全球监管,打赢新冠大流行这场硬仗

Publisher's note: the English language version of this article may be found here .  新冠疫情激起了全球医药产业的广泛响应, 许多公司正将其专精与技术投入其中, 开发疫苗和疗法。 然而, 在不同国家或地区的监管上, 我们还没有看到全球总协同。 相反, 许多监管上的决策只局限于不同的国家层面, 让全产业的努力显得支离破碎...
BioCentury | Apr 22, 2020
Regulation

All for one, one for all: An urgent call to harmonize global drug regulation against COVID-19

The COVID-19 pandemic has spurred enormous activity in the drug industry around the world with many companies pooling their expertise and technologies to develop vaccines and treatments. However, we have no visible global coordination of...
BioCentury | Apr 11, 2020
Product Development

Collaboration, standardization will bring access to convalescent plasma and answers about its efficacy

Academic institutions, companies and government agencies have added convalescent plasma to the growing list of interventions being brought under centralized protocols to treat COVID-19. Large-scale, coordinated trials such as master protocols are gaining traction in...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...
Items per page:
1 - 10 of 866
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

AsclepiX intends to use its $35 million series A round for proof-of-concept studies of its lead product in three retinal disease indications, while also developing peptides into therapeutic candidates for oncology. Spun out of The...
BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

CAR T liver fibrosis therapy  Memorial Sloan Kettering Cancer Center researchers have generated CAR T cells against PLAUR, which is involved in extracellular matrix remodelling, that could eliminate pathologic senescent cells . Senescent cells have been...
BioCentury | Jun 4, 2020
Product Development

WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial

In the latest hit to hydroxychloroquine, a double-blind, placebo-controlled study found that use of the malaria drug as post-exposure prophylaxis doesn’t prevent COVID-19. The report comes as the WHO resumes hydroxychloroquine testing in SOLIDARITY, and...
BioCentury | Apr 29, 2020
Product Development

Thrive AACR data highlights specificity, sensitivity trade-offs for cancer screening

Data from Thrive’s prospective, multicancer blood test study makes it clear that avoiding false positives is the top priority when screening asymptomatic individuals for rare events. While that inevitably comes at the cost of sensitivity,...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

Fibrosis company Avalyn raises $35.5M series B  Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 24, 2020
Regulation

人人为我,我为人人: 协调全球监管,打赢新冠大流行这场硬仗

Publisher's note: the English language version of this article may be found here .  新冠疫情激起了全球医药产业的广泛响应, 许多公司正将其专精与技术投入其中, 开发疫苗和疗法。 然而, 在不同国家或地区的监管上, 我们还没有看到全球总协同。 相反, 许多监管上的决策只局限于不同的国家层面, 让全产业的努力显得支离破碎...
BioCentury | Apr 22, 2020
Regulation

All for one, one for all: An urgent call to harmonize global drug regulation against COVID-19

The COVID-19 pandemic has spurred enormous activity in the drug industry around the world with many companies pooling their expertise and technologies to develop vaccines and treatments. However, we have no visible global coordination of...
BioCentury | Apr 11, 2020
Product Development

Collaboration, standardization will bring access to convalescent plasma and answers about its efficacy

Academic institutions, companies and government agencies have added convalescent plasma to the growing list of interventions being brought under centralized protocols to treat COVID-19. Large-scale, coordinated trials such as master protocols are gaining traction in...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes on a new dimension in the U.K., and the spotlight on its biopharmas to respond with countermeasures beyond physical...
Items per page:
1 - 10 of 866